MGMT and glioblastoma: While MGMT promoter methylation is a known prognostic factor for outcome among GBM patients specifically associated with TMZ efficacy (41), its influence remains uncertain in PGS patients with varying reports on frequency of MGMT promoter methylation and its association with OS.